Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction

[1]  Jian Yu,et al.  BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade , 2021, Oncogene.

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  Xiang Guo,et al.  The application and prospect of CDK4/6 inhibitors in malignant solid tumors , 2020, Journal of Hematology & Oncology.

[4]  G. Rosner,et al.  Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). , 2018, Leukemia research.

[5]  C. Austin,et al.  Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response , 2018, Oncotarget.

[6]  W. Tap,et al.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. , 2018, Cancer cell.

[7]  Gen Sheng Wu,et al.  Developing TRAIL/TRAIL death receptor-based cancer therapies , 2018, Cancer and Metastasis Reviews.

[8]  R. Mesa,et al.  Combined venetoclax and alvocidib in acute myeloid leukemia , 2017, Oncotarget.

[9]  W. El-Deiry,et al.  The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia , 2017, Cell cycle.

[10]  P. Sicinski,et al.  Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.

[11]  Jian Yu,et al.  FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation , 2016, Oncogene.

[12]  M. Malumbres,et al.  Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases , 2016, Nature Reviews Molecular Cell Biology.

[13]  A. Letai,et al.  Mitochondria-Judges and Executioners of Cell Death Sentences. , 2016, Molecular cell.

[14]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[15]  Jian Yu,et al.  BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs , 2014, Proceedings of the National Academy of Sciences.

[16]  Jian Yu,et al.  TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity , 2014, Oncotarget.

[17]  E. Chu An update on the current and emerging targeted agents in metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  M. Chen,et al.  A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. , 2010, Surgical oncology.

[20]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[21]  A. Ashkenazi,et al.  Directing cancer cells to self-destruct with pro-apoptotic receptor agonists , 2008, Nature Reviews Drug Discovery.

[22]  J. Pietenpol,et al.  The jury is in: p73 is a tumor suppressor after all. , 2008, Genes & development.

[23]  Jian Yu,et al.  Downregulation of Dkk3 activates β-catenin/TCF-4 signaling in lung cancer , 2008 .

[24]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[25]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[26]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[27]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.